Publications

Detailed Information

Early Compliance and Efficacy of Sublingual Immunotherapy in Patients with Allergic Rhinitis for House Dust Mites

DC Field Value Language
dc.contributor.authorChang, Hyun-
dc.contributor.authorHan, Doo Hee-
dc.contributor.authorMo, Ji-hun-
dc.contributor.authorKim, Jeong-Whun-
dc.contributor.authorLee, Chul Hee-
dc.contributor.authorRhee, Chae-Seo-
dc.contributor.authorMin, Yang-Gi-
dc.contributor.authorKim, Dong-Young-
dc.date.accessioned2012-07-05T00:44:27Z-
dc.date.available2012-07-05T00:44:27Z-
dc.date.issued2009-09-
dc.identifier.citationCLINICAL AND EXPERIMENTAL OTORHINOLARYNGOLOGY; Vol.2 3; 136-140ko_KR
dc.identifier.issn1976-8710-
dc.identifier.urihttps://hdl.handle.net/10371/78524-
dc.description.abstractObjectives. Sublingual immunotherapy (SLIT) has recently received much attention around the world as a treatment for allergic rhinitis. This study aimed to investigate the efficacy and adverse effects of SLIT in Korean patients with allergic rhinitis caused by house dust mites. The treatment compliance and the patient satisfaction with SLIT were also assessed. Methods. The patients who were sensitized to Dermatophagoides pteronyssinus and Dermatophagoides farinae and who started SLIT between November 2007 and July 2008 were included in this study. The symptom questionnaires, which included items on rhinorrhea, sneezing, nasal obstruction, itchy nose, olfactory disturbance, eye discomfort and sleep disturbance, were obtained before and 6 months after SLIT. The patient satisfaction and the adverse effects were also investigated. Results. One hundred forty-two patients started SLIT and 98 of them continued SLIT for 6 months or more. Ninety-two of the 98 patients completed the questionnaires. The duration of receiving SLIT was 9.8 months on average (range, 6 to 13 months). All the symptoms of allergic rhinitis were improved with SLIT. Forty-five percent of the patients were satisfied for SLIT, while 12% were unsatisfied. The incidence of adverse effects was 12% during maintenance therapy, although it was 48% during the up-dosing phase. The drop-out rate of SLIT was 31.0%. Conclusion. The subjective symptoms were improved with SLIT in Korean patients with allergic rhinitis for house dust mites. Yet the drop out rate was high despite of the symptomatic improvement.ko_KR
dc.language.isoenko_KR
dc.publisherKOREAN SOC OTORHINOLARYNGOLko_KR
dc.subjectAllergic rhinitisko_KR
dc.subjectImmunotherapyko_KR
dc.subjectComplianceko_KR
dc.titleEarly Compliance and Efficacy of Sublingual Immunotherapy in Patients with Allergic Rhinitis for House Dust Mitesko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor장현-
dc.contributor.AlternativeAuthor한두희-
dc.contributor.AlternativeAuthor모지헌-
dc.contributor.AlternativeAuthor김정훈-
dc.contributor.AlternativeAuthor김동영-
dc.contributor.AlternativeAuthor이철희-
dc.contributor.AlternativeAuthor민양기-
dc.contributor.AlternativeAuthor이재서-
dc.identifier.doi10.3342/ceo.2009.2.3.136-
dc.citation.journaltitleCLINICAL AND EXPERIMENTAL OTORHINOLARYNGOLOGY-
dc.description.citedreferenceRoder E, 2008, CLIN EXP ALLERGY, V38, P1659, DOI 10.1111/j.1365-2222.2008.03060.x-
dc.description.citedreferenceEsch RE, 2008, CURR OPIN OTOLARYNGO, V16, P260-
dc.description.citedreferenceFrew AJ, 2008, NEW ENGL J MED, V358, P2259-
dc.description.citedreferenceBOUSQUET J, 2008, ALLERGY S, V86, P8-
dc.description.citedreferenceEifan AO, 2007, ALLERGY, V62, P567, DOI 10.1111/j.1398-9995.2006.01301.x-
dc.description.citedreferenceDunsky EH, 2006, ALLERGY, V61, P1235, DOI 10.1111/j.1398-9995.2006.01137.x-
dc.description.citedreferenceAntico A, 2006, ALLERGY, V61, P1236, DOI 10.1111/j.1398-9995.2006.01155.x-
dc.description.citedreferenceDahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003-
dc.description.citedreferenceDurham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358-
dc.description.citedreferencePasslacqua G, 2006, J ALLERGY CLIN IMMUN, V117, P946, DOI 10.1016/j.jaci.2005.12.1312-
dc.description.citedreferenceCanonica GW, 2006, ALLERGY, V61, P20-
dc.description.citedreferencePASSALACQUA G, 2006, INFLAMM ALLERGY DRUG, V5, P43-
dc.description.citedreferenceRIENZO VD, 2005, CLIN EXP ALLERGY, V35, P560-
dc.description.citedreferenceKIM DY, 2004, KOREAN J OTOLARYNGOL, V47, P132-
dc.description.citedreferenceWILSON DR, 2003, COCHRANE DB SYST REV, P2893-
dc.description.citedreferenceNUHOGLU Y, 2003, J INVESTIG ALLERGOL, V17, P375-
dc.description.citedreferenceLombardi C, 2001, ALLERGY, V56, P989-
dc.description.citedreferenceGuez S, 2000, ALLERGY, V55, P369, DOI 10.1034/j.1398-9995.2000.00413.x-
dc.description.citedreferencePurello-D`Ambrosio F, 1999, ALLERGY, V54, P968-
dc.description.citedreferencePradalier A, 1999, ALLERGY, V54, P819-
dc.description.citedreferenceDurham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356-
dc.description.citedreferenceCASANOVAS M, 1994, J INVEST ALLERG CLIN, V4, P305-
dc.description.tc6-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share